WHAT: PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today introduced new workstations and a high content screening system at SLAS2020 in San Diego (booth #929). These technologies automate workflows so that disease research and drug discovery professionals can improve productivity, increase reproducibility, and garner key insights.
PerkinElmer will highlight these new systems, along with several key offerings from its comprehensive portfolio of instruments and reagents at SLAS2020:
JANUS® G3 Blood iQ™ Workstation: for biobanking workflows, it offers front end reformatting of plasma and buffy coat layers from centrifuged blood tubes, enabling highly reproducible, downstream genetic analysis.
Sciclone® G3 NGSx HT Workstation: helps simplify the miniaturization of NGS library prep. Coupled with a new NEXTFLEX® Rapid XP DNA-seq kit, this library preparation workflow is designed to enable researchers to increase their NGS throughput while decreasing their cost per reaction.
Opera Phenix® Plus High Content Screening System: for fast response analysis of physiologically relevant model systems, this enhancement to PerkinElmer’s high content imaging platform adds fast frame rate image capture for assays such as cardiomyocyte beat rate monitoring. It also offers an optional liquid handling module to enable assays like Ca2+ flux, important to the study of neurological diseases such as Alzheimer’s, Huntington’s, and Parkinson’s.
Designed to drive more relevant testing earlier in the drug discovery process, the Opera Phenix Plus system can also be used with two cell cultures, primary cells, 3D organoids, spheroids and microtissues.
PerkinElmer will also showcase additional technologies that enable disease research and life sciences: LabChip® GX Touch™ Nucleic Acid Analyzer; explorer™ G3 Integrated Workstations; MuviCyte™ Live-Cell Imaging Kit; VICTOR® Nivo™ Multimode Microplate Reader; EnVision® Multimode Plate Reader; and EnSight™ Multimode Plate Reader.
SLAS attendees can learn about PerkinElmer’s industry-leading no-wash assay technologies including the Alpha, LANCE® Ultra™ and HTRF® assays. The Alpha CETSA® assays combine PerkinElmer’s Alpha and Pelago Biosciences' Cellular Thermal Shift assays (CETSA®), which enable the assessment of target engagement in cell-based assays and generate more physiologically-relevant results.
These products are for research use only. Not for use in diagnostic procedures.
WHY: “Advancing disease research and bringing new drugs to market quickly is often supported by innovative testing and analysis solutions that deliver fast, more accurate and reproducible results and novel insights,” said Alan Fletcher, VP/GM, Life Sciences at PerkinElmer. “These new offerings will help scientists and technicians meet key needs across critical lab workflows as they leverage our robust portfolio, spanning from instruments and software, plate readers and integrated workstations, to assays, reagents and services.”
MORE: PerkinElmer’s experts will also deliver the following presentations at SLAS2020:
Monday, January 27, 2020
“The Importance of Sample Management in Precision Medicine: A High-Throughput Biobanking Workflow Solution” presented along with expert from the Brooks Life Sciences and Rutgers University Cell and DNA Repository (RUCDR), 12:30 p.m. – 1:15 p.m., Room #11A.
“An Automated Deep-Learning Workflow for Analyzing HCS Screens” 2:00 p.m. – 2:45 p.m., Room #11B
Tuesday, January 28, 2020
“Technical and Workflow Considerations for cfDNA Applications” 9:30 – 10:15 a.m., Room #9
“Taking the Guesswork Out of NGS Library Prep Reaction Miniaturization” 2:00 – 2:45 p.m., Room #9
PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and health care. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food, and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 13,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $2.8 billion in 2018, serves customers in more than 180 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.